September 28, 2021
Productive discussion regarding “made-in-Ontario COVID-19 vaccine candidate” BURLINGTON, Ontario – September 28, 2021- Yesterday afternoon, Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) welcomed Premier Doug Ford and Caucus member Stephen Crawford MPP, to their head office and manufacturing facility in Burlington, Ontario...
September 15, 2021
Pre-clinical testing has demonstrated manufacturing stability and statistically significant antibody production BURLINGTON, Ontario – September 15, 2021- Today, Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) and McMaster University (“McMaster”) are reporting a preliminary, yet significant milestone in the investigation of an orally...
August 26, 2021
FOR IMMEDIATE RELEASE BURLINGTON, Ontario – August 25, 2021- Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), today reported its Q1 financial results. “The Company is on a path of transformation and is well-positioned to drive innovation and our business plan forward as...
August 26, 2021
FOR IMMEDIATE RELEASE BURLINGTON, Ontario – August 25, 2021- Rapid Dose Therapeutics Corp. (“RDT” or the“Company”) (CSE: DOSE), today reported its financial results for the year ended February 28, 2021. “The Company achieved a number of key milestones this year, is transitioning efficiently into its...
August 10, 2021
TORONTO, ONTARIO, August 10, 2021 – Rapid Dose Therapeutics Corp. (the “Company”) (CSE: DOSE) is providing a bi-weekly update on the status of the management cease trade order granted on June 29, 2021 (the “MCTO”) by its principal regulator, the Ontario Securities Commission, in accordance...
July 30, 2021
BURLINGTON, Ontario July 30, 2021 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), announces, pursuant to its Stock Option Plan, the granting of incentive stock options to purchase 2,100,000 common shares at an exercise price of $0.65 per share. Each has a...
July 27, 2021
TORONTO, ONTARIO, July 27, 2021 – Rapid Dose Therapeutics Corp. (the “Company”) (CSE: DOSE) is providing a bi-weekly update on the status of the management cease trade order granted on June 29, 2021 (the “MCTO”) by its principal regulator, the Ontario Securities Commission, in accordance...
July 22, 2021
Rapid Dose Therapeutics Announces the Appointment of Advisory Board Ron Brooks, CPA, CA, ICD.D, Nick DiRenzo, FCA, FCPA, ICD.D and Anne Lachance, ICD.D appointed to help support the Company’s global expansion BURLINGTON, Ontario – July 22, 2021- Rapid Dose Therapeutics Corp. (“RDT” or the “Company”)...
July 20, 2021
Rapid Dose Therapeutics and McMaster University Enter Next Stage of COVID-19 QuickStrip™ Vaccine Research Ahead of Schedule Pre-clinical in vivo testing expected to prove efficacy of QuickStrip technology in the delivery of vaccines BURLINGTON, Ontario – July 20, 2021- Rapid Dose Therapeutics Corp. (“RDT”...
July 14, 2021
Rapid Dose Provides Bi-Weekly Status Report Regarding Management Cease Trade Order and Update Regarding Interim Financial Statements TORONTO, ONTARIO, July 13, 2021 – Rapid Dose Therapeutics Corp. (the “Company”) (CSE: DOSE) is providing a bi-weekly update on the status of the management cease trade order...